Retatrutide, a innovative dual-acting glucose-regulated incretin analog, represents a significant progression in peptide treatments for the management of type 2 diabetic conditions and, increasingly, weight issues. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor stimula